No Data
Stock Blogger Sanasae: Only 2 months left in the Dragon year market in 2024! Keep an eye on the outstanding topic stocks 【FISCO Social Reporter】
The following is a comment written by individual investor 'Sanasae,' a Fisco Social Reporter (Blog: 'Sanasae's Beautiful Investment Life'). At Fisco, we strive to collaborate with individuals who actively share information, aiming to provide a wider range of information to all investors. ------------ *Written on October 28, 2024 at 7:00 pm Everyone, good morning/afternoon/evening. In the blink of an eye, this year, 2024, is about to enter its final two months.
Pay attention to biochemistry and SIG Group.
On the 16th, in the US stock market yesterday, the Dow Jones Industrial Average closed at 43,077.70, up 337.28 points, while the Nasdaq Composite Index closed at 18,367.08, up 51.49 points. The Chicago Nikkei 225 futures on the Osaka day session were up 260 yen at 39,450 yen. The exchange rate was 1 dollar = 149.50-60 yen. In today's Tokyo market, Hamakyore <9037> announced a share buyback with a limit of 0.27% of the issued shares and a purchasing commission, with total revenue in September increasing by 11.9% from the 7.3% increase in August, expanding the growth rate.
Volume Change Rate Ranking (9 o'clock) - Kyukoh Yakuhin, Koshidaka HD, etc. are ranked.
※In the volume change rate ranking, you can understand the market participants' interests, such as trends in speculative activity, by comparing the average volume of the last 5 days with the volume on the delivery day. ■Volume Change Rate Top [As of 9:32 on October 11] (Comparison with the average volume of the last 5 days) Stock Code Stock Name Volume 5-day Average Volume Volume Change Rate Stock Price Change Rate ＜2625＞ iFTPX Year 4 207,692 107,185.08 301.98% 0.00
Daiseki Eco Solution: Interim report - 29th term (2024/03/01-2025/02/28)
Daiseki Eco. Solution's Attributable Profit Falls 45% in H1
October 1st [Today's investment strategy]
[Fisco Selected Brands] [Material Brands] Nexera Pharma <4565> ¥1226 (10/1) Drug discovery venture. Former Sosei Group. Subsidiary Nexera Pharma Japan has announced the conclusion of a partnership agreement with Otsuka Pharmaceutical <4507> regarding the distribution and sales of the insomnia treatment drug "Cubic Tablets" in Japan, and the termination of sales efforts with Takeda Pharmaceutical <4534>. Otsuka Pharmaceutical will now independently carry out distribution and sales activities in Japan. [Emerging Markets
No Data
No Data